ストックスクリーナーアプリを入手
1.77
3.21%
0.055
Transcode Therapeutics Inc (RNAZ) 最新ニュース
Natera Partners With TransCode to Advance Colorectal Cancer Trial - Zacks Investment Research
No approved treatment exists for colorectal cancer patients with cancer signals but clear scans. A trial will test one. - Stock Titan
TransCode Therapeutics Eases Near-Term Obligations Under Financing - The Globe and Mail
TransCode Therapeutics Eases Near-Term Obligations Under Financing - TipRanks
Form 8K Transcode Therapeutics Inc For: 1 October By Investing.com - Investing.com India
With a waiver through October 31, TransCode Therapeutics (RNAZ) pays Yorkville. - Stock Titan
After 98 doses, TransCode (RNAZ) reports no adverse events that led patients to stop treatment. - Stock Titan
Transcode Therapeutics Inc (NASDAQ: RNAZ) Share Price, RNAZ Stock News, RNAZ Share Price & Updates - Kalkine
TransCode Therapeutics Share PriceRNAZ, RNS News, Articles, Quotes, & Charts (NASDAQ:RNAZ) - Proactive financial news
TransCode Therapeutics CFO Resigns, Interim Replacement Named - minichart.com.sg
Form 8K Transcode Therapeutics Inc For: 11 September By Investing.com - Investing.com Nigeria
Form 8K Transcode Therapeutics Inc For: 11 September By Investing.com - Investing.com South Africa
Transcode Therapeutics announces CFO resignation and interim appointment - Investing.com
Transcode Therapeutics announces CFO resignation and interim appointment - Investing.com
TransCode Therapeutics Announces CFO Resignation and Interim Appointment - TipRanks
Form 8K Transcode Therapeutics Inc For: 11 September By Investing.com - Investing.com Canada
Form 8K Transcode Therapeutics Inc For: 11 September By Investing.com - Investing.com UK
Transcode Therapeutics (RNAZ) grants CFO 185,000 options with 10-year term - Stock Titan
CFO exit at TransCode Therapeutics (RNAZ) comes with severance tied to future funding - Stock Titan
TransCode Therapeutics Appoints Interim CFO Following Retirement of Tom Fitzgerald - citybuzz -
TransCode Therapeutics Appoints John Tattory As Interim CFO - TradingView
Transcode Therapeutics, Inc. Announces CFO Changes, Effective September 10, 2026 - marketscreener.com
Join TransCode Therapeutics' Live Investor Webinar: Advancing a Multi-Platform Oncology Pipeline Targeting Metastatic Cancer - Yahoo Finance
An RNA-based treatment showed a survival benefit in mice with breast cancer spread to bone - Stock Titan
RNAZ Stock Price, Quote & News - Syfe
TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-than-Expected Loss of $150.64 Per Share Weighs on SharesEarnings Yield Spread - vinanet.vn
TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-than-Expected Loss of $150.64 Per Share Weighs on SharesEarnings Growth Forecast - dars.gov.et
TransCode Therapeutics (RNAZ) Q4 2024 Earnings: Wider-than-Expected Loss of $150.64 Per Share Weighs on SharesEarnings Per Share - dars.gov.et
TransCode Therapeutics (NASDAQ: RNAZ) logs $24.5M loss and funding strain - Stock Titan
TransCode Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
TransCode Therapeutics (RNAZ) Holds Above $3.50 as Shares Grind Higher in Quiet SessionExhaustion Gap - vinanet.vn
TransCode Therapeutics (RNAZ) Advances 3.26% to $3.48, Approaching Key Resistance at $3.65Sector Neutral Pair - vinanet.vn
TransCode Therapeutics (RNAZ) Holds Above $3.50 as Shares Grind Higher in Quiet SessionMFI Oversold - careplusvn.com
TransCode Therapeutics (RNAZ) Advances 3.26% to $3.48, Approaching Key Resistance at $3.65High Yield Stocks - dars.gov.et
TransCode Therapeutics (RNAZ) Holds Above $3.50 as Shares Grind Higher in Quiet SessionLow Vol ETF - dars.gov.et
Transcode Therapeutics Inc (RNAZ) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Transcode Therapeutics Inc (RNAZ) Stock News Today - TradingKey
Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - ACCESS Newswire
Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - Corsicana Daily Sun
Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - Yahoo! Finance Canada
Virax Biolabs and Transcode Therapeutics Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV - Yahoo Finance
Why (RNAZ) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Major holder converts preferred shares at Transcode Therapeutics, Inc. (RNAZ) - stocktitan.net
Transcode Therapeutics (RNAZ) major holders disclose convertible preferred stake - Stock Titan
TransCode Therapeutics Updates Preferred Stock Governance Terms - The Globe and Mail
TransCode Therapeutics Updates Preferred Stock Governance Terms - TipRanks
DEFJ lifts TransCode Therapeutics (RNAZ) stake to 83.9% after conversions - Stock Titan
TransCode Therapeutics (RNAZ) Retreats 2.7% to $4.62, Approaching Key Support ZoneSynthetic Short - vinanet.vn
TransCode Therapeutics Q4 2024 Earnings: Wider-than-Expected Loss of -$150.64 Per Share Signals Ongoing Clinical-Stage Cash BurnFinancial Health Score - siam.in
Unleash Immuno Oncolytics (RNAZ holder) reports 9.94% TransCode Therapeutics stake - Stock Titan
3.09%
0.72%
大文字化:
|
ボリューム (24 時間):